RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > BMS' Opdivo Wins UK EAMS Approval for Hodgkin's Lymphoma

BMS' Opdivo Wins UK EAMS Approval for Hodgkin's Lymphoma

Posted 03 November 2016 | By Michael Mezher 

BMS' Opdivo Wins UK EAMS Approval for Hodgkin's Lymphoma

The Medicines and Healthcare products Regulatory Agency (MHRA) on Thursday accepted Bristol-Myers Squibb's Opdivo (nivolumab) to its early access to medicines scheme (EAMS) to treat relapsed or refractory Hodgkin's lymphoma.

Previously, MHRA granted access to Opdivo under EAMS for patients with certain types of lung cancer, kidney cancer and melanoma.


In March 2014, MHRA announced it was launching EAMS, saying it would allow earlier access to potentially lifesaving medicines for patients with severe or life-threatening conditions.

For a product to qualify for EAMS, it must be granted a promising innovative medicine (PIM) designation based on early (Phase I and/or II) clinical data and satisfy additional criteria including the severity of the condition the product is intended to treat and the level of improvement over previously authorized treatments.

Since EAMS approval is based on early clinical data, companies are required to provide MHRA with regular reports documenting adverse effects, and should notify the agency of changes to treatment protocols based on data gathered through the product's use.

Because these products are not yet licensed in the UK, MHRA says a positive EAMS assessment is intended to "inform doctors who may wish to prescribe the unlicensed medicine under their own responsibility," such as in cases where other options have been exhausted. Additionally, MHRA says that a positive EAMS assessment should not be considered to be an indication of future authorization of a product.

EAMS Scientific Opinion

According to MHRA, the drug was accepted to EAMS for its potential to reduce tumor size after multiple attempts with other therapies.

Alongside the scientific opinion, MHRA has also issued treatment protocols for patients and healthcare professionals, as well as instructions for pharmacovigilance reporting for patients treated with the drug under EAMS.



© 2022 Regulatory Affairs Professionals Society.